Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Michigan’s health ... Affordable Care Act and the Healthy Michigan Plan. Throughout ... Komen remains a trusted funding resource for under-served individuals. ... assist uninsured or underinsured women between the ages of ... below 250 percent of the federal poverty level. ...
(Date:9/2/2014)... Plano, Texas (PRWEB) September 02, 2014 ... Expo, Prosupps will be an exhibitor at ... 3150 Paradise Rd, Las Vegas, NV 89109 Booth #374 ... vision is to encourage healthy living through exercise, diet ... to this vision, and provide the tools for all ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: Health ... heart failure guidelines, according to the results of ... Congress by Professor Aldo Maggioni. Clinical variables explained ... said: "This is a unique evaluation which combines ... countries. It provides a fuller picture of the ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Attorney Robert ... the 2015 "Lawyer of the Year" for Medical Malpractice ... & Meyer PC, Boston, and has been selected for inclusion ... Only one lawyer in each practice area and designated metropolitan ... on particularly impressive voting averages received during the peer-review assessments. ...
(Date:9/2/2014)... BC (PRWEB) September 02, 2014 ... pioneer in Canada announced today the expansion of its ... the company’s first Chief Financial Officer. Liang joins AURO ... Web Hosting, and will work closely with the operations, ... on expanding their cloud presence as well as ensuring ...
Breaking Medicine News(10 mins):Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... A new decades-long study launches today to investigate whether there ... long-term health problems such as cancer. The cohort study ... and Health Research (MTHR) Programme. The international study will run ... least 250,000 participants aged 18-69 in five European countries. The ...
... led by an Oregon Health & Science University Knight ... be used to help identify physicians who might ... Patricia A. Carney, Ph.D., OHSU School of Medicine professor ... Medicine; and associate director of Cancer Prevention, Control and ...
... ... EcoAdvisor for Earth Day. , ... Midland (PRWEB) April 22, 2010 -- In honour of Earth Day, OnlyGreen has planted 365 ... Mokugift, an official partner of the United Nations Environment Programme,s Plant for the Planet: Billion ...
... far most common choice of discipline , THURSDAY, April 22 ... American parents, but new research suggests it might still be ... conducted for C.S. Mott Children,s Hospital at the University of ... spank their child in some scenarios, said poll director Dr. ...
... ... ... management has come a long way in the last few decades. Advent of modern eye ... , ,We are excited though to tell about the latest technique Dr. Khanna is using ...
... ... LifeLinks innovative Spanish video interpreting services for the price of phone-only interpreting services. ... New York, ... breakthrough Spanish language interpretation. Pay the same for LifeLinks Spanish video interpretation service as ...
Cached Medicine News:Health News:Health impacts of mobile phone use to be explored in huge new study 2Health News:Health impacts of mobile phone use to be explored in huge new study 3Health News:Physicians who interpret mammograms may benefit from additional training 2Health News:Physicians who interpret mammograms may benefit from additional training 3Health News:OnlyGreen Plants 365 Trees for Earth Day 2010 2Health News:One in Five Parents Would Spank in Certain Settings 2Health News:One in Five Parents Would Spank in Certain Settings 3Health News:Glued graft for Pterygium Yield Better Cosmetic Results 2Health News:Glued graft for Pterygium Yield Better Cosmetic Results 3Health News:LifeLinks Revolutionizes Video Interpreting, Shows Spanish Interpreting in Added Dimension-VIDEO! 2
... ANA is an enzyme-linked immunosorbent assay (ELISA) ... (ANA) in human serum. The presence of ... clinical findings and other laboratory tests to ... such as systemic lupus erythematosus, Sjgren's syndrome, ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
Medicine Products: